Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
| NCT ID | NCT02268851 |
| Title | A Phase I/Ib Safety and Efficacy Study of the PI3K-delta Inhibitor TGR-1202 and Ibrutinib in Patients With CLL or MCL |
| Recruitment | Active, not recruiting |
| Gender | both |
| Phase | Phase I |
| Variant Requirements | No |
| Sponsors | Dana-Farber Cancer Institute |
| Indications | |
| Therapies | |
| Age Groups: | adult |
| Covered Countries | USA |
| Facility | Status | City | State | Zip | Country | Details |
|---|---|---|---|---|---|---|
| Pacific Cancer Care | Monterey | California | 93940 | United States | Details | |
| St. Francis Hospital and Cancer Center | Hartford | Connecticut | 06105 | United States | Details | |
| Eastern Maine Medical Center/ Northern Light Cancer Care | Brewer | Maine | 04412 | United States | Details | |
| Dana Farber Cancer Institute | Boston | Massachusetts | 02115 | United States | Details | |
| Beth Israel Deaconness Medical Center | Boston | Massachusetts | 02215 | United States | Details |